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The lomaiviticins (1 and 2) and kinamycins (3–5) are bacterial metabolites with potent antimicrobial
and antiproliferative activities. Herein we establish that 1–5 are capable of generating electrophilic
acylfulvene intermediates (6) under mildly reducing conditions. These acylfulvenes 6 are formed by
a multistep process comprising two-electron reduction and loss of dinitrogen to form an ortho-quinone
methide, followed by elimination. Based on these studies, the structure of the product formed from 1 in
DNA-cleavage assays is proposed (26). We also show that the bis(hydroxynaphthoquinone)
substructures of the lomaiviticins activate the metabolites toward reduction. Finally, based on
COMPARE and time-dependent cell response profiling analyses, we show that kinamycin C (4) and the
monomeric lomaiviticin aglycon (24) operate by a mechanism of action that is distinct from simple
diazofluorenes, such as 23.
Introduction
The quinone methide occupies an eminent position in nature’s
molecular arsenal. Frequently, this functional group behaves as
a powerful electrophile, and this reactivity forms the basis for the
cytotoxicity of many natural products and drugs.1 Here we
present evidence that the diazobenzo[b]fluorene (diazofluorene)
antitumor antibiotics the lomaiviticins (1 and 2)2 and the kin-
amycins (3–5)3 form quinone methides which do not react by
nucleophilic addition but instead undergo an elimination reac-
tion to produce electrophilic acylfulvene intermediates (see 6,
Fig. 1a).4 This mode of reactivity was first postulated by Moore
over 30 years ago for the kinamycins,5 but experimental evidence
for its feasibility has not been reported, so far as we are aware.
The cellular target(s) of the lomaiviticins and kinamycins are
currently not known. Members of both classes of metabolites
have been reported to cleave dsDNA in the presence of
a reducing co-factor in vitro2,6 and in tissue culture.7 Hasinoff
and Dmitrienko have also provided evidence that kinamycin F
Fig. 1 (a) Acylfulvene intermediate (6) implicated by this work. (b)
Intermediates (7–9) previously proposed to form from the kinamycins
and lomaiviticins. (c) Structure of a model diazofluorene previously
studied (10) and the diazofluorenes used in this work (11, 12).
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(5) targets a protein in the cyclic D3 production pathway.8 The
structural dissimilarities between 1, 2 and 3–5 also raise the
possibility that different mechanisms of action are operative.9
Several studies aimed at elucidating the chemical behaviour of
diazofluorenes have been described.10 These findings established
the high reactivity of this functional group toward reducing
agents and nucleophiles. Based on these prior results, several
reaction manifolds have been proposed to underlie the cytotoxic
effects of 1–5. These include intracellular reduction to form vinyl
radicals (7, Fig. 1b)6,10b–d and quinone methide intermediates
(8),6,10b–f nucleophilic attack to produce covalent adducts such as
9,10b and generation of reactive oxygen species by redox cycling of
the quinone.6b,7 All in vitro mechanistic studies have employed
substrates which contain an aromatic D-ring, such as dimethyl-
prekinamycin (10, Fig. 1c).
Results
Our studies have focused on the diazofluorenes 11 and 12, which
contain an ether substituent on the D-ring (Fig. 1c). The diazo-
fluorene 11 was prepared according to the sequence outlined in
Scheme 1.11 The synthesis began with 4-(S)-[(4-methoxybenzyl)
oxy]cyclohex-2-ene-1-one (13),12 which was homologated to the
b-(trimethylsilylmethyl)cyclohexenone 14 by a three-step
sequence (49% overall). Fluoride-mediated coupling of 14 with
2,3-dibromo-5,8-dimethoxynaphthoquinone then formed the g-
alkylation product 15 (87%). Cyclization of 15, mediated by
palladium acetate in the presence of silver carbonate, generated
the ortho-quinone methide 16 (62%). Finally, diazo transfer to
the ortho-quinone methide 16 produced the synthetic diazo-
fluorene 11 in 97% yield.
We found that the diazofluorene 11 was indefinitely stable as
a solid or in solutions of aprotic, non-nucleophilic solvents at
ambient temperature. In contrast, under mildly reducing condi-
tions in protic solvents 11 reacted rapidly (Scheme 2). Thus,
treatment of a methanolic solution of 11 with dithiothreitol
(DTT; [11] ¼ [DTT] ¼ 20 mM) and warming to 37 C produced
the methoxy-substituted ortho-quinone methide 17. In a prepar-
ative-scale experiment, 17 was obtained in 80% isolated yield
after 24 h. The experiments outlined below establish that the
pathway from 11 to 17 comprises: (1) reduction of the diazo
function of 11 to form the ortho-quinone methide 16; (2) elimi-
nation of para-methoxybenzyl alcohol from 16 to generate the
acylfulvene intermediate 18; (3) 1,6-addition of methanol to 18 to
provide the methyl ether product 17.
The following lines of evidence support this reaction pathway.
First, we found that the diazofluorene 11 was stable for at least
24 h in methanol, which argues against direct SN2 displacement
of para-methoxybenzyl alcohol from 11. Second, LC/MS moni-
toring of the reduction–solvolysis confirmed that the ortho-
quinone methide 16 was formed; at 30% conversion of 11, the
ratio of 11 to 16 was 3 : 1 (Fig. 2). Since the ortho-quinone
methide 16 is the penultimate synthetic precursor to the diazo-
fluorene 11 (Scheme 1), we were able to unequivocally establish
its presence in solution by LC/MS co-injection with an authentic
sample. Circular dichroism (CD) analysis of isolated 17 revealed
that it was optically inactive, supporting the generation of an
achiral intermediate, such as 18. Finally, monitoring the reduc-
tion–solvolysis of 11 simultaneously by LC/MS and CD analysis
established a correlation between conversion to 17 and loss of
optical activity, indicating that neither 11 nor 16 racemize under
the reaction conditions (see ESI†).
We also studied the solvolysis of the isolated quinone methide
16 directly (16/ 17). Under neutral conditions in methanol at
Scheme 1 Synthesis of the diazofluorene 11: Reagents and conditions: (a)
TMSCH2MgCl, CuI, THF,60 C, then HMPA, Et3N, TMSCl,60/
24 C; (b) PhSeCl, THF, 78 C, 78% (two steps); (c) H2O2, CH2Cl2, 24
C, 63%; (d) 2,3-dibromo-5,8-dimethoxynaphthoquinone, TASF(Et),
THF, 78 C, 87%; (e) Pd(OAc)2, polymer-supported triphenylphos-
phine, Ag2CO3, toluene, 80
C, 62%; (f) TfN3, Et3N, CH3CN, 0 C, 97%.
Scheme 2 Reduction–solvolysis of the diazofluorene 11.
Fig. 2 Reduction–solvolysis of the diazofluorene 11: (-) diazofluorene
11, (A) ortho-quinone methide 16, (C) methyl ether 17. Reagents and
conditions: 11 (200 mM), DTT (200 mM), 1% CH2Cl2–CH3OH, 37
C.
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37 C, the half-life for solvolysis was 10 h, and in a preparative-
scale experiment, 17 was isolated in 96% yield (see ESI†).
Addition of trichloroacetic acid (1 equiv) decreased the half-life
for solvolysis to 2.4 h, whereas addition of triethylamine (1
equiv) increased the half-life of 16 to approximately 51 h. Under
strongly basic conditions (1 equiv sodium methoxide), the
solvolysis occurred smoothly, albeit more slowly, with a half-life
of 161 h.
To gain insight into the effects of the phenol substituents of the
lomaiviticins on this reduction–elimination pathway, we
prepared the bis(hydroxy)diazofluorene 12 (Scheme 3). Analo-
gous to the bis(methyl ether) 11, treatment of 12 with DTT in
methanol formed the expected ortho-quinone methide (20) and
solvolysis (21) products. Although the intermediates in this series
showed partial decomposition after 4 h in solution, this experi-
ment revealed that 12 is reduced three-fold faster than 11 (60%
conversion of 12 and 21% conversion of 11 after 30 min, see
ESI†). This enhanced reactivity suggests that the phenol
substituents of the lomaiviticins activate the metabolites for
reduction.13
To translate our findings to phenotype-based assays, we
assessed the antiproliferative properties of diazofluorenes 11
and 12, the simpler constructs 22 and 23,14 the monomeric
lomaiviticin aglycon 24,11b the ortho-quinone methide 16, and
kinamycin C (4, Table 1).15 Our results establish that analogs
bearing free phenols are more potent than those with aryl
methyl ethers (compare 12 to 11), possibly due to the increased
rate of reduction of the former. Furthermore, the presence of
a reductively-labile oxygen substituent on the D-ring leads to
an approximately two-fold increase in activity (12 vs. 22).
Surprisingly, however, certain analogs possessing a D-ring with
a quaternary center (23) exhibited high potency, suggesting that
mechanisms other than reductive activation may contribute to
these molecules’ cytotoxic effects. These assays also show that
isolated ortho-quinone methides such as 16 are inactive. This
may be due to rapid degradation in cell culture; less than 40%
of 16 remained after warming to 37 C for 15 h in LNCaP cell
lysate.
We generated time-dependent cell response profiles (TCRPs)
by measuring cell culture impedance as a function of time for
kinamycin C (4), the diazofluorene 23, and the monomeric
lomaiviticin aglycon 24, employing the A172 cell line. This
technique has previously been used to assess similarities
between natural products’ mechanisms of action.16 As shown in
Fig. 3, the TCRPs of kinamycin C (4) and the monomeric
lomaiviticin aglycon 24 are similar but distinct from the diaz-
ofluorene 23. Moreover, a COMPARE analysis of the anti-
cancer activities of 2317 and kinamycin C (4) in the NCI 60-cell
line panel18 reveals a poor correlation (r ¼ 0.527).19 These data
show that these diazofluorenes operate by distinct or multiple
mechanisms of action.
Discussion
The experiments outlined above demonstrate that the lomaivi-
ticins and kinamycins undergo reduction to ortho-quinone
methide products under biologically-relevant conditions.
Although such intermediates were generated in earlier
studies,10c,d,f these experiments were conducted under abiotic
conditions (catalytic hydrogenation or tributyltin hydride/
AIBN) and employed planar, aromatic substrates, such as pre-
kinamycin dimethyl ether (10). By using the more functionalized
substrates 11 and 12, we have revealed that the D-ring of these
metabolites is reactive as well. The chemistry we have observed
was first proposed byMoore in 1977,5 but has not been evaluated
experimentally.
In the early 1990s, it was shown that various glycosylated
anthracyclines undergo reduction followed by expulsion of an
aminosugar residue to form vinylogous ortho-quinone methide
intermediates.20 The experiments described herein suggest that
the lomaiviticins follow a similar pattern of reactivity. Moreover,
ESI/MS analysis of DNA-cleavage assays, employing lomaiviti-
cin A (1) and DTT as reductant, revealed a product consistent
with loss of dinitrogen and an aminosugar residue, and incor-
poration of one equivalent each of dihydrogen and methanol.21
However, the complexity of lomaiviticin A (1) and small sample
size prevented rigorous determination of the structure at that
time. In light of our observations, we propose the structure of
this product as the methyl ether 26 (Scheme 4), and suggest 26 is
formed by reduction–elimination to the acylfulvene 25, followed
by 1,6-addition of methanol.22
Our cell viability data suggest multiple mechanisms of action
underlie the biological activity of synthetic diazofluorenes.
Specifically, analogs such as 23, which do not contain a reduc-
tively-labile D-ring substituent, retain potent cytotoxic prop-
erties, but clearly operate by a mechanism of action that is
distinct from those that do, such as kinamycin C (4) and the
monomeric lomaiviticin aglycon 24. In retrospect this is not
surprising; several quinone-based anticancer agents, such as the
mitomycins and anthracyclines,20,23 manifest two or more
chemical pathways that contribute to cytotoxicity, although in
the case of the mitomycins, cross-linking of DNA is of the
greatest biological significance. Finally, the inactivity of iso-
lated ortho-quinone methides (e.g., 16) suggests reduction
occurs after cellular entry and/or binding of the diazofluorenes
to their target(s). An alternative interpretation of this result is
that cytotoxicity arises directly from the diazofluorene itself.10b
However, the different TCRPs of 4 and 24 compared to 23, as
well as our COMPARE analysis, argue against this.
Scheme 3 Synthesis of the diazofluorene 12 and structures of the ortho-
quinone methides 20 and 21. Reagents and conditions: (a) 2,3-dibromo-
5,8-bis(methoxymethyloxy)naphthoquinone, TASF(Et), CH2Cl2, 78
C, 99%; (b) Pd(OAc)2, polymer-supported triphenylphosphine, Ag2CO3,
toluene, 80 C, 33%; (c) TfN3, Et3N, CH3CN, 0 C, 71%; (d) HCl–
CH3OH, 78/ 20 C, 59%.
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Conclusion
Our studies have established a reductively-activated elimination
pathway for the lomaiviticins and kinamycins and allow us to
provide a plausible structure for the product formed from
lomaiviticin A (1) in DNA-cleavage assays. Although the
primary mechanism of action of 1 and 2 has yet to be established,
the mild conditions and time-scale within which reduction and
solvolysis occur suggest that this pathway is viable in tissue
culture. Additionally, our structure–function studies reveal an
activating role for the hydroxy groups of the lomaiviticins and
show that isolated ortho-quinone methides (e.g., 16) are unstable
under cellular conditions. Delineating the significance of these
various pathways and intermediates as they relate to the
observed cytotoxic effects of the lomaiviticins will be the focus of
future research.
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